ARTICLE | Company News
Maxim Pharmaceuticals other research news
December 4, 2000 8:00 AM UTC
MAXM received a $100,000 Phase I SBIR grant from the National Cancer Institute to conduct preclinical testing to treat cancer with its MX2060 compound, which may induce the expression of apoptosis-sti...